Opinion
Video
Author(s):
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
OncLive’s May Roundup of Key FDA Approvals in Oncology
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
FDA Advisory Committee Recommends Approval of Shield Blood Test for CRC Detection in Average-Risk Adults
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC
Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC
Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC